Literature DB >> 10984492

New structural and functional aspects of the type I interferon-receptor interaction revealed by comprehensive mutational analysis of the binding interface.

J Piehler1, L C Roisman, G Schreiber.   

Abstract

Type I interferons bind to two cell surface receptors, ifnar1 and ifnar2, as the first step in the activation of several signal transduction pathways that elicit an anti-viral state and an anti-proliferative response. Here, we quantitatively mapped the complete binding region of ifnar2 on interferon (IFN)alpha2 by 35 individual mutations to alanine and isosteric residues. Of the six "hot-spot" residues identified (Leu-30, Arg-33, Arg-144, Ala-145, Met-148, and Arg-149), four are located on the E-helix, which is located at the center of the binding site flanked by residues on the A-helix and the AB-loop. The contribution of residues of the D-helix, which have been previously implicated in binding, proved to be marginal for the interaction with the extracellular domain of ifnar2. Interestingly, the ifnar2 binding site overlaps the largest continuous hydrophobic patch on IFNalpha2. Thus, hydrophobic interactions seem to play a significant role stabilizing this interaction, with the charged residues contributing toward the rapid association of the complex. Relating the anti-viral and anti-proliferative activity of the various interferon mutants with their affinity toward ifnar2 results in linear function over the whole range of affinities investigated, suggesting that ifnar2 binding is the rate-determining step in cellular activation. Dose-time analysis of the anti-viral response revealed that shortening the incubation time of low-level activation cannot be compensated by higher IFN doses. Considering the strict dependence of the cellular response on affinity, these results suggest that for maintaining transcription of IFN-responsive genes over a longer time period, low but continuous signaling through the IFN receptor is essential.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10984492     DOI: 10.1074/jbc.M006854200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

1.  Structure of the interferon-receptor complex determined by distance constraints from double-mutant cycles and flexible docking.

Authors:  L C Roisman; J Piehler; J Y Trosset; H A Scheraga; G Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-06       Impact factor: 11.205

Review 2.  Cytokine-receptor interactions as drug targets.

Authors:  Gideon Schreiber; Mark R Walter
Journal:  Curr Opin Chem Biol       Date:  2010-07-07       Impact factor: 8.822

3.  Lateral ligand-receptor interactions on membranes probed by simultaneous fluorescence-interference detection.

Authors:  Martynas Gavutis; Suman Lata; Peter Lamken; Pia Müller; Jacob Piehler
Journal:  Biophys J       Date:  2005-03-18       Impact factor: 4.033

4.  Determination of the two-dimensional interaction rate constants of a cytokine receptor complex.

Authors:  Martynas Gavutis; Eva Jaks; Peter Lamken; Jacob Piehler
Journal:  Biophys J       Date:  2006-02-10       Impact factor: 4.033

5.  The EM structure of a type I interferon-receptor complex reveals a novel mechanism for cytokine signaling.

Authors:  Zongli Li; Jennifer Julia Strunk; Peter Lamken; Jacob Piehler; Thomas Walz
Journal:  J Mol Biol       Date:  2007-12-08       Impact factor: 5.469

6.  Stochastic receptor expression determines cell fate upon interferon treatment.

Authors:  Doron Levin; Daniel Harari; Gideon Schreiber
Journal:  Mol Cell Biol       Date:  2011-06-20       Impact factor: 4.272

7.  Designing cell-targeted therapeutic proteins reveals the interplay between domain connectivity and cell binding.

Authors:  Avi Robinson-Mosher; Jan-Hung Chen; Jeffrey Way; Pamela A Silver
Journal:  Biophys J       Date:  2014-11-18       Impact factor: 4.033

8.  Total chemical synthesis of human interferon alpha-2b via native chemical ligation.

Authors:  Jing Li; Clara Lehmann; Xishan Chen; Fabio Romerio; Wuyuan Lu
Journal:  J Pept Sci       Date:  2015-03-24       Impact factor: 1.905

9.  Type I interferon gene therapy protects against cytomegalovirus-induced myocarditis.

Authors:  Vanessa S Cull; Emmalene J Bartlett; Cassandra M James
Journal:  Immunology       Date:  2002-07       Impact factor: 7.397

Review 10.  Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation.

Authors:  Jacob Piehler; Christoph Thomas; K Christopher Garcia; Gideon Schreiber
Journal:  Immunol Rev       Date:  2012-11       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.